Global biopharmaceutical powerhouse Teva Pharmaceutical Industries is setting its sights on a major growth leap, targeting $6–7 billion in innovative medicines revenue by 2030 and positioning its expanding drug pipeline to deliver potentially one new medicine launch every year over the next five years.

 

At its first-ever Research and Development (R&D) Day, the company laid out an ambitious roadmap for its next phase of growth, highlighting a pipeline with more than $10 billion in potential peak sales, an expanding antibody discovery programme and a strategy aimed at turning scientific advances into commercial success.

 

The announcement marks a significant milestone in Teva's transformation under its Pivot to Growth strategy, launched in 2023. The company says it has more than doubled revenue from innovative medicines since the strategy began and has returned to investment-grade credit status.

 

“With our Pivot to Growth strategy, we set out to transform Teva,” said Richard Francis, Teva’s President and CEO. “Since then, we have more than doubled our innovative medicines revenue, built a pipeline with more than $10 billion in peak sales potential, and returned to investment grade. 

 

"We’ve made meaningful progress, driven by teams that are bringing together the speed and agility of a biotech with the scale and capabilities of a global biopharmaceutical company. Our R&D engine and commercial excellence are designed to translate proven science into new medicines, with the potential for one new launch annually through 2030, driving revenue growth, margin expansion and strong cash generation.”

 

Teva's next growth phase will be driven by a combination of late-stage drug candidates, emerging antibody technologies and investments in areas including immunology, oncology and inflammatory diseases.

 

Among the key programmes highlighted at the R&D Day are:

 

Anti-IL-15: Teva reported that its Phase 2a study in celiac disease met its primary endpoint, with a Phase 2b study expected to begin in the second half of 2027. Its investigational candidate TEV-'408 is also advancing into a Phase 2/3 study for vitiligo, following encouraging Phase 1b results. The company is evaluating its potential in additional conditions, including alopecia.

 

ATTENUKINE (Anti-PD-1/IL-2): The investigational cancer treatment is currently in Phase 1 development for advanced cancer. Teva said early efficacy signals and a favourable safety profile have been observed so far.

 

Next-generation antibodies: The company is advancing precision antibody candidates, including anti-TSLP/IL-13 and anti-TL1A/IL-23, targeting potential new treatments for asthma and inflammatory bowel disease.

 

The company is also highlighting its in-house antibody discovery capabilities, which it believes will strengthen its ability to develop differentiated treatments and accelerate its research pipeline.

 

Teva is banking on a research model that combines proven science, internal discovery capabilities and external partnerships to accelerate drug development and bring promising candidates closer to market.

 

The company says its late-stage pipeline now includes seven high-value assets with combined potential peak sales exceeding $10 billion, subject to regulatory approvals.

 

It also pointed to faster development timelines across several programmes. These include WELTRUZA, which advanced directly from Phase 1 into Phase 3, ecopipam receiving FDA priority review, and the advancement of anti-IL-15 in vitiligo through a seamless Phase 2/3 programme.

 

Alongside research investments, Teva is relying on its global commercial infrastructure, analytics and market-access expertise to support product launches and expand the reach of its innovative medicines.

 

The transformation is already beginning to reshape Teva's business.

 

The company said innovative medicines now account for more than 20% of its total revenue, while gross margin has improved to approximately 55% as of the third quarter of 2026.

 

Its three key innovative products — AUSTEDO (deutetrabenazine), AJOVY (fremanezumab-vfrm) and UZEDY (risperidone) — are expected to grow by more than approximately 125% by the end of 2026. Teva has also recently launched WELTRUZA (olanzapine).

 

Beyond innovative medicines, the company said it has stabilised its generics business, while revenue from biosimilars is expected to double between 2024 and 2026.

 

Teva generated more than $6 billion in free cash flow between 2023 and 2025, providing financial capacity to support its next phase of investment and expansion.

 

Teva's financial ambitions extend well beyond the growth of its drug pipeline.

 

The company has outlined the following targets through 2030:

 

Innovative medicines revenue: $6–7 billion.

Innovative medicines gross margin: Above 75%.

 

Total revenue: Mid-single-digit annual growth between 2026 and 2030.

 

Free cash flow: More than $3.5 billion by 2030.

Debt reduction: A path to net debt-to-adjusted EBITDA of 2.0x by the end of 2027.

 

Capital allocation: Continued investment in research, product launches and strategic business development, alongside shareholder returns.

 

The projected increase in innovative medicines' contribution is expected to drive margin expansion and strengthen cash generation.

 

Teva's return to investment-grade credit status in 2026 is another important pillar of the strategy, giving the company a stronger financial foundation to fund pipeline development, commercial launches and targeted acquisitions or partnerships.

 

Teva's R&D Day signals a company looking to move beyond its traditional generics-led identity and establish itself as a high-velocity biopharmaceutical player.

 

Its ambition to deliver one innovative medicine launch annually through 2030 will depend on the successful progression of clinical candidates, regulatory approvals and the company's ability to commercialise new treatments at scale.

 

With seven late-stage pipeline assets, ten innovative programmes and two clinical antibodies discovered in-house, Teva is betting that its combination of research capabilities, global reach and financial discipline can sustain its next growth cycle.

 

The $6–7 billion revenue ambition is significant, but execution will be the real test. Clinical outcomes, regulatory decisions and commercial uptake will ultimately determine whether the company's expanding pipeline can translate into lasting growth.

 

All pipeline products remain investigational and are subject to clinical development and regulatory approval. Peak sales estimates are non-risk-adjusted and indicative.